Although the benefits of thrombolytic therapy are well established in patients younger than age 75 years with acute ST-elevation myocardial infarction, the value of thrombolytic treatment in ...

Methodologic problems with this meta-analysis that cause difficulties in accepting the conclusion of efficacy of thrombolysis in AMI include the following: The criterion for inclusion into the ...

Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded ...

The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.

Roche’s Genentech unit has received approval from the US Food and Drug Administration (FDA) for TNKase (tenecteplase) in ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...

Hyperglycemia is associated with adverse outcomes in patients with acute coronary syndromes ... Adjunctive Reperfusion Therapy–Thrombolysis In Myocardial Infarction 28 (CLARITY–TIMI 28 ...

In 2023, Roche said it was removing TNKase for stroke from its phase 3 programmes after a readout of the TIMELESS trial, but ...